Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant tislelizumab plus capecitabine versus capecitabine alone after resection of biliary tract carcinoma
ChiCTR2400088474Phase 2Completed
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
- Start
- Jul 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of tislelizumab and capecitabine in biliary cancer, cholangiocarcinoma (CCA) and gallbladder cancer (2 arms), sponsored by Eastern Hepatobiliary Surgery Hospital. Primary endpoint: Recurrence-free survival. Started Jul 2023; status: completed.
02
Drugs
tislelizumabcapecitabine
03
Conditions
biliary cancercholangiocarcinoma (CCA)gallbladder cancer
Beyond the preview
Go deeper on ChiCTR2400088474.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400088474.